• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据美国预防服务工作组的资格标准,评估肺癌筛查用计算机断层扫描的适宜性。

Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task Force.

机构信息

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.

Department of Health Services Research and Administration, University of Nebraska Medical Center, Omaha.

出版信息

JAMA Netw Open. 2022 Nov 1;5(11):e2243163. doi: 10.1001/jamanetworkopen.2022.43163.

DOI:10.1001/jamanetworkopen.2022.43163
PMID:36409492
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9679877/
Abstract

IMPORTANCE

Currently, computed tomography (CT) is used for lung cancer screening (LCS) among populations with various levels of compliance to the eligibility criteria from the US Preventive Services Task Force (USPSTF) recommendations and may represent suboptimal allocation of health care resources.

OBJECTIVE

To evaluate the appropriateness of CT LCS according to the USPSTF eligibility criteria.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used the 2019 Behavioral Risk Factor Surveillance System (BRFSS) survey. Participants included individuals who responded to the LCS module administered in 20 states and had valid answers to questions regarding screening and smoking history. Data were analyzed between October 2021 and August 2022.

EXPOSURES

Screening eligibility groups were categorized according to the USPSTF 2013 recommendations, and subgroups of individuals who underwent LCS were analyzed.

MAIN OUTCOMES AND MEASURES

Main outcomes included LCS among the screening-eligible population and the proportions of the screened populations according to compliance categories established from the USPSTF 2013 and 2021 recommendations. In addition, the association between respondents' characteristics and LCS was evaluated for the subgroup who were screened despite not meeting any of the 3 USPSTF screening criteria: age, pack-year, and years since quitting smoking.

RESULTS

A total of 96 097 respondents were identified for the full study cohort, and 2 subgroups were constructed: (1) 3374 respondents who reported having a CT or computerized axial tomography to check for lung cancer and (2) 33 809 respondents who did not meet any screening eligibility criteria. The proportion of participants who were under 50 years old was 53.1%; between 50 and 54, 9.1%; between 55 and 79, 33.8%; and over 80, 4.0%. A total of 51 536 (50.9%) of the participants were female. According to the USPSTF 2013 recommendation, 807 (12.8%) of the screening-eligible population underwent LCS. Among those who were screened, only 807 (20.9%) met all 3 screening eligibility criteria, whereas 538 (20.1%) failed to meet any criteria. Among respondents in subgroup 2, being of older age and having a history of stroke, chronic obstructive pulmonary disease, kidney disease, or diabetes were associated with higher likelihood of LCS.

CONCLUSIONS AND RELEVANCE

In this cross-sectional study of the BRFSS 2019 survey, the low uptake rate among screening-eligible patients undermined the goal of LCS of early detection. Suboptimal screening patterns could increase health system costs and add financial stress, psychological burden, and physical harms to low-risk patients, while failing to provide high-quality preventive services to individuals at high risk of lung cancer.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16e5/9679877/6bf4ab12d881/jamanetwopen-e2243163-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16e5/9679877/9fa444c4e316/jamanetwopen-e2243163-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16e5/9679877/88564fbf7b8a/jamanetwopen-e2243163-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16e5/9679877/6bf4ab12d881/jamanetwopen-e2243163-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16e5/9679877/9fa444c4e316/jamanetwopen-e2243163-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16e5/9679877/88564fbf7b8a/jamanetwopen-e2243163-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16e5/9679877/6bf4ab12d881/jamanetwopen-e2243163-g003.jpg
摘要

重要性

目前,计算机断层扫描(CT)用于具有不同程度符合美国预防服务工作组(USPSTF)建议的肺癌筛查(LCS)资格标准的人群,并且可能代表医疗保健资源的分配不合理。

目的

根据 USPSTF 的资格标准,评估 CT LCS 的适宜性。

设计、地点和参与者:这项横断面研究使用了 2019 年行为风险因素监测系统(BRFSS)调查。参与者包括对在 20 个州进行的 LCS 模块做出回应且对筛查和吸烟史有有效答案的个人。数据于 2021 年 10 月至 2022 年 8 月之间进行分析。

暴露

根据 USPSTF 2013 年的建议,将筛查合格人群分为不同组别,同时分析了接受 LCS 的亚组。

主要结果和措施

主要结果包括符合筛查条件的人群中的 LCS 情况,以及根据 USPSTF 2013 年和 2021 年建议建立的合规类别,根据筛选结果对筛选人群的比例。此外,还评估了受访者特征与尽管不符合 USPSTF 3 项筛查标准中的任何一项(年龄、吸烟年数和戒烟年数)但仍接受 LCS 的亚组之间的关系。

结果

共有 96097 名受访者被确定为整个研究队列的成员,并构建了 2 个亚组:(1)3374 名报告曾进行 CT 或计算机轴向断层扫描以检查肺癌的患者;(2)33809 名不符合任何筛查资格标准的患者。年龄在 50 岁以下的参与者比例为 53.1%;在 50 至 54 岁之间,为 9.1%;在 55 至 79 岁之间,为 33.8%;在 80 岁以上,为 4.0%。共有 51536 名(50.9%)参与者为女性。根据 USPSTF 2013 年的建议,有 807 名(12.8%)符合筛查条件的人群接受了 LCS。在接受筛查的人群中,只有 807 名(20.9%)符合所有 3 项筛查资格标准,而 538 名(20.1%)不符合任何标准。在亚组 2 的受访者中,年龄较大且有中风、慢性阻塞性肺疾病、肾病或糖尿病病史的人更有可能进行 LCS。

结论和相关性

在这项对 2019 年 BRFSS 调查的横断面研究中,符合筛查条件的患者的低接受率破坏了早期发现肺癌的 LCS 目标。不理想的筛查模式可能会增加医疗系统的成本,并给低风险患者带来经济压力、心理负担和身体伤害,同时未能为高风险肺癌患者提供高质量的预防服务。

相似文献

1
Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task Force.根据美国预防服务工作组的资格标准,评估肺癌筛查用计算机断层扫描的适宜性。
JAMA Netw Open. 2022 Nov 1;5(11):e2243163. doi: 10.1001/jamanetworkopen.2022.43163.
2
Lung Cancer Screening in the US, 2022.2022 年美国肺癌筛查
JAMA Intern Med. 2024 Aug 1;184(8):882-891. doi: 10.1001/jamainternmed.2024.1655.
3
Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data.肺癌筛查的使用情况以及不同种族和族裔的不同资格标准的影响:2019 年行为风险因素监测系统数据。
Cancer. 2022 May 1;128(9):1812-1819. doi: 10.1002/cncr.34098. Epub 2022 Feb 24.
4
Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.肺癌低剂量计算机断层扫描筛查的获益与危害评估:美国预防服务工作组的建模研究。
JAMA. 2021 Mar 9;325(10):988-997. doi: 10.1001/jama.2021.1077.
5
Screening for lung cancer: 2023 guideline update from the American Cancer Society.肺癌筛查:美国癌症协会 2023 年指南更新。
CA Cancer J Clin. 2024 Jan-Feb;74(1):50-81. doi: 10.3322/caac.21811. Epub 2023 Nov 1.
6
Racial and Ethnic Disparities in Lung Cancer Screening Eligibility.肺癌筛查资格中的种族和民族差异。
Radiology. 2021 Dec;301(3):712-720. doi: 10.1148/radiol.2021204691. Epub 2021 Sep 21.
7
Evaluation of Revised US Preventive Services Task Force Lung Cancer Screening Guideline Among Women and Racial/Ethnic Minority Populations.修订版美国预防服务工作组肺癌筛查指南在女性和少数族裔人群中的评估。
JAMA Netw Open. 2021 Jan 4;4(1):e2033769. doi: 10.1001/jamanetworkopen.2020.33769.
8
Lung Cancer Screening in Brazil Comparing the 2013 and 2021 USPSTF Guidelines.巴西的肺癌筛查:比较 2013 年和 2021 年 USPSTF 指南。
JAMA Netw Open. 2023 Dec 1;6(12):e2346994. doi: 10.1001/jamanetworkopen.2023.46994.
9
Revisiting the lung cancer screening eligibility criteria to promote equity for Black individuals.重新审视肺癌筛查资格标准,以促进黑人群体的公平性。
Lung Cancer. 2024 May;191:107539. doi: 10.1016/j.lungcan.2024.107539. Epub 2024 Mar 20.
10
Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems.评估与 2021 年美国预防服务工作组肺癌筛查建议相关的基于社区的医疗保健系统中的人群水平变化。
JAMA Netw Open. 2021 Oct 1;4(10):e2128176. doi: 10.1001/jamanetworkopen.2021.28176.

引用本文的文献

1
Facilitators and barriers of lung cancer screening participation: umbrella and systematic review of the global evidence.肺癌筛查参与的促进因素和障碍:全球证据的综合及系统评价
BMC Public Health. 2025 Sep 1;25(1):2993. doi: 10.1186/s12889-025-23808-8.
2
Characteristics of the Newly Eligible Population under Two Recent Updates of Lung Cancer Screening Recommendations.肺癌筛查建议最近两次更新下新符合条件人群的特征
Cancer Prev Res (Phila). 2025 Jun 2;18(6):365-373. doi: 10.1158/1940-6207.CAPR-24-0465.
3
Estimating the Burden of False Positives and Implementation Costs From Adding Multiple Single Cancer Tests or a Single Multi-Cancer Test to Standard-Of-Care Screening.

本文引用的文献

1
Factors associated with low-dose CT lung cancer screening participation in a high burden state: Results from the 2017-2018 BRFSS.与高负担州低剂量 CT 肺癌筛查参与相关的因素:来自 2017-2018 年 BRFSS 的结果。
J Cancer Policy. 2021 Jun;28:100284. doi: 10.1016/j.jcpo.2021.100284. Epub 2021 Apr 5.
2
Total and Out-of-Pocket Costs of Procedures After Lung Cancer Screening in a National Commercially Insured Population: Estimating an Episode of Care.全国商业保险人群肺癌筛查后程序的总费用和自付费用:估计一个疗程的护理。
J Am Coll Radiol. 2022 Jan;19(1 Pt A):35-46. doi: 10.1016/j.jacr.2021.09.015. Epub 2021 Oct 1.
3
评估在标准护理筛查中增加多项单一癌症检测或一项多癌症检测所产生的假阳性负担和实施成本。
Cancer Med. 2025 Mar;14(6):e70776. doi: 10.1002/cam4.70776.
4
A Novel Automated Algorithm to Identify Lung Cancer Screening from Free Text of Radiology Orders.一种从放射学检查申请的自由文本中识别肺癌筛查的新型自动化算法。
J Gen Intern Med. 2025 May;40(6):1306-1314. doi: 10.1007/s11606-025-09429-2. Epub 2025 Feb 25.
5
Lung Cancer Screening Participation Among Indigenous Peoples Worldwide: A Systematic Review of Challenges and Opportunities.全球原住民的肺癌筛查参与情况:挑战与机遇的系统评价
Health Promot J Austr. 2025 Apr;36(2):e70001. doi: 10.1002/hpja.70001.
6
Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST).中国国家癌症筛查(CHANCES)试验和乳腺断层合成钼靶成像筛查试验(TMIST)中的设计考量与挑战。
J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):42-48. doi: 10.1093/jncimonographs/lgae049.
7
Identifying the population to be targeted in a lung cancer screening programme in Denmark.确定丹麦肺癌筛查计划中的目标人群。
BMJ Open Respir Res. 2024 Dec 25;11(1):e002499. doi: 10.1136/bmjresp-2024-002499.
8
The Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside.一种新型尿液生物传感器平台在肺癌检测决策过程中的潜在益处:从实验室到临床
J Clin Med. 2024 Oct 16;13(20):6164. doi: 10.3390/jcm13206164.
9
Accelerating progress to reduce the cancer burden through prevention and control in the United States.通过在美国进行预防和控制来加速减轻癌症负担的进程。
J Natl Cancer Inst. 2025 Jan 1;117(1):20-28. doi: 10.1093/jnci/djae204.
10
The risk and benefit profiles of US-eligible lung cancer screening attendees vs nonattendees.符合美国肺癌筛查条件的参与者与非参与者的风险和获益情况。
J Natl Cancer Inst. 2024 Dec 1;116(12):1896-1903. doi: 10.1093/jnci/djae148.
Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.
肺癌筛查:CHEST 指南和专家小组报告。
Chest. 2021 Nov;160(5):e427-e494. doi: 10.1016/j.chest.2021.06.063. Epub 2021 Jul 13.
4
Updated Analysis of Complication Rates Associated With Invasive Diagnostic Procedures After Lung Cancer Screening.肺癌筛查后侵袭性诊断程序相关并发症发生率的更新分析。
JAMA Netw Open. 2020 Dec 1;3(12):e2029874. doi: 10.1001/jamanetworkopen.2020.29874.
5
Lung cancer screening eligibility and use with low-dose computed tomography: Results from the 2018 Behavioral Risk Factor Surveillance System cross-sectional survey.肺癌筛查资格和低剂量计算机断层扫描的使用:来自 2018 年行为风险因素监测系统横断面调查的结果。
Cancer. 2021 Mar 1;127(5):748-756. doi: 10.1002/cncr.33322. Epub 2020 Nov 18.
6
Lung Cancer Screening Uptake: Analysis of BRFSS 2018.肺癌筛查的接受情况:2018年美国国家健康访问调查分析
J Gen Intern Med. 2021 Sep;36(9):2897-2899. doi: 10.1007/s11606-020-06236-9. Epub 2020 Sep 21.
7
Risk-Based lung cancer screening: A systematic review.基于风险的肺癌筛查:一项系统综述。
Lung Cancer. 2020 Sep;147:154-186. doi: 10.1016/j.lungcan.2020.07.007. Epub 2020 Jul 12.
8
Screening for Lung Cancer - 10 States, 2017.肺癌筛查 - 10 个州,2017 年。
MMWR Morb Mortal Wkly Rep. 2020 Feb 28;69(8):201-206. doi: 10.15585/mmwr.mm6908a1.
9
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.随机试验中 CT 容积筛查降低肺癌死亡率
N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.
10
Lung Cancer Screening Uptake in the United States.美国肺癌筛查的接受情况。
Chest. 2020 Jan;157(1):236-238. doi: 10.1016/j.chest.2019.08.2176.